9/18/2008

The FDA is set to hand down by Friday its decisions on GlaxoSmithKline's Promacta and Roche Holding's Actemra, a move that may boost the drugmakers' market shares. Citigroup analysts estimated that by 2012, Promacta -- a drug to treat a rare blood disorder -- could generate $509.6 million, while Actemra -- a rheumatoid arthritis medicine -- could bring in $638 million.

Full Story:
Reuters

Related Summaries